

# Comparative analysis of clinical breakpoints, normalized resistance interpretation and epidemiological cut-offs in interpreting antimicrobial resistance of *Escherichia coli* isolates originating from poultry in different farm types in Tanzania

Maganga, Ruth; Sindiyo, Emmanuel; Musyoki, Victor Moses; Shirima, Gabriel; Mmbaga, Blandina T

DOI:  
[10.1099/acmi.0.000540.v4](https://doi.org/10.1099/acmi.0.000540.v4)

License:  
Creative Commons: Attribution (CC BY)

*Document Version*  
Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*  
Maganga, R, Sindiyo, E, Musyoki, VM, Shirima, G & Mmbaga, BT 2023, 'Comparative analysis of clinical breakpoints, normalized resistance interpretation and epidemiological cut-offs in interpreting antimicrobial resistance of *Escherichia coli* isolates originating from poultry in different farm types in Tanzania', *Access Microbiology*, vol. 5, no. 7, 000540. <https://doi.org/10.1099/acmi.0.000540.v4>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Download date: 27. Apr. 2024

# Comparative analysis of clinical breakpoints, normalized resistance interpretation and epidemiological cut-offs in interpreting antimicrobial resistance of *Escherichia coli* isolates originating from poultry in different farm types in Tanzania

Ruth Maganga<sup>1,2,3,\*</sup>, Emmanuel Sindiyoy<sup>4</sup>, Victor Moses Musyoki<sup>5</sup>, Gabriel Shirima<sup>4</sup> and Blandina T. Mmbaga<sup>3</sup>

## Abstract

**Introduction.** Existing breakpoint guidelines are not optimal for interpreting antimicrobial resistance (AMR) data from animal studies and low-income countries, and therefore their utility for analysing such data is limited. There is a need to integrate diverse data sets, such as those from low-income populations and animals, to improve data interpretation.

**Gap statement.** There is very limited research on the relative merits of clinical breakpoints, epidemiological cut-offs (ECOFFs) and normalized resistance interpretation (NRI) breakpoints in interpreting microbiological data, particularly in animal studies and studies from low-income countries.

**Aim.** The aim of this study was to compare antimicrobial resistance in *Escherichia coli* isolates using ECOFFs, CLSI and NRI breakpoints.

**Methodology.** A total of 59 non-repetitive poultry isolates were selected for investigation based on lactose fermentation on MacConkey agar and subsequent identification and confirmation as *E. coli* using chromogenic agar and *uidA* PCR. Kirby Bauer disc diffusion was used for susceptibility testing. For each antimicrobial agent, inhibition zone diameters were measured, and ECOFFs, CLSI and NRI bespoke breakpoints were used for resistance interpretation.

**Results.** According to the interpretation of all breakpoints except ECOFFs, tetracycline resistance was significantly higher (TET) (67.8–69.5%), than those for ciprofloxacin (CIPRO) (18.6–32.2%), imipenem (IMI) (3.4–35%) and ceftazidime (CEF) (1.7–45.8%). Prevalence estimates of AMR using CLSI and NRI bespoke breakpoints did not differ for CEF (1.7% CB and 1.7% CO<sub>WT</sub>), IMI (3.4% CB and 4.0% CO<sub>WT</sub>) and TET (67.8% CB and 69.5% CO<sub>WT</sub>). However, with ECOFFs, AMR estimates for CEF, IMI and CIP were significantly higher (45.8, 35.6 and 64.4%, respectively;  $P < 0.05$ ). Across all the three breakpoints, resistance to ciprofloxacin varied significantly (32.2% CB, 64.4% ECOFFs and 18.6% CO<sub>WT</sub>;  $P < 0.05$ ).

**Conclusion.** AMR interpretation is influenced by the breakpoint used, necessitating further standardization, especially for microbiological breakpoints, in order to harmonize outputs. The AMR ECOFF estimates in the present study were significantly higher compared to CLSI and NRI.

Received 12 December 2022; Accepted 13 June 2023; Published 14 July 2023

**Author affiliations:** <sup>1</sup>University of Birmingham, Birmingham, B15 2TT, UK; <sup>2</sup>University of Glasgow, Glasgow, G12 8QQ, UK; <sup>3</sup>Kilimanjaro Christian Medical Center/Kilimanjaro Clinical Research Institute, PO Box 2236, Moshi, Tanzania; <sup>4</sup>The Nelson Mandela African Institution of Science and Technology, PO Box 447, Arusha, Tanzania; <sup>5</sup>Department of Medical Microbiology, University of Nairobi, PO Box 19676-00202, Nairobi, Kenya.

\*Correspondence: Ruth Maganga, rsm921@student.bham.ac.uk

**Keywords:** breakpoints; antimicrobial resistance; susceptibility; resistance interpretation; *Escherichia coli*; inhibition zone diameter; normalized resistance interpretation; epidemiological cut-offs.

**Abbreviations:** AMR, antimicrobial resistance; CB, clinical breakpoint; CEF, ciprofloxacin; CLSI, Clinical and Laboratory Standards Institute; CO<sub>WT</sub>, normalized resistance interpretation breakpoint; ECOFF, epidemiological cut-off; IMI, imipenem; IZD, inhibition zone diameter; NRI, normalized resistance interpretation; NWT, non-wild-type; TET, tetracycline.

One supplementary file is available with the online version of this article.

000540.v4 © 2023 The Authors



This is an open-access article distributed under the terms of the Creative Commons Attribution License.

## DATA SUMMARY

Data used in the current study are provided in the supplementary material. Sheet 1 (EUCAST and MYDATA) presents a breakdown (in proportion) of the isolates per zone diameter. Additionally, it provides data on the proportion of EUCAST reference isolates per zone diameter. Distribution curves were generated from both sets of data in sheet 1 using EUCAST distribution curves as a reference. Sheet 2 (Molecular and Phenotypic results) shows 74 isolates that were shipped to Glasgow for further analysis including 59 isolates that were positive for *Escherichia coli* following *uidA* PCR, which were subsequently used for downstream analysis to produce distribution curves that were then compared to reference EUCAST distribution.

## INTRODUCTION

Antimicrobial resistance (AMR) has emerged as a major public health concern due to the rapidly diminishing efficacy of antimicrobial therapy [1]. Phenotypic approaches have long been acknowledged as the gold standard for detecting resistance both in clinical and in microbiological contexts [2]. Despite the prominence of molecular approaches, phenotypic techniques remain crucial for quantifying resistance and sensitivity, whereas genotypic techniques are useful for predicting resistance and determining resistance mechanisms [3]. Susceptibility testing is commonly used in clinical settings to determine how bacteria respond to empirical therapy, and one of the most popular criteria for determining if an antimicrobial is effective is estimating the lowest dosage at which microbial growth may be suppressed [3–5]. Well-known susceptibility metrics include inhibition zone diameter (IZD) and minimum inhibitory concentration (MIC) [5]. In the MIC assessment, micro-organisms are cultured in liquid media in the case of broth microdilution in slots with varying concentrations of the antimicrobial agent under study, ranging from high to low, and the lowest MIC score inhibiting growth of microbes is then determined [5]. IZDs are usually measured on solid media, in which antimicrobial discs of known concentrations are placed on plates streaked with bacteria culture, the antimicrobials diffuse away from the disc, generating a concentration gradient that inhibits bacterial growth at a measurable radius from the disc, resulting in a zone of inhibition [5, 6]. The wider the inhibition zone, the easier it is to treat the population of micro-organisms being examined.

Selecting a breakpoint guideline to adopt is largely driven by the objective of the analysis [7, 8]. AMR in clinical and microbiological contexts differs greatly, as do the functions of breakpoints [8]. In clinical settings, the term ‘resistance’ refers to a condition in which a patient’s clinical recovery requirements are not met while receiving the correct antimicrobial dosage [8–10]. By contrast, in a microbiological context, resistance pertains to the mechanisms that make an isolate less susceptible to an antimicrobial agent compared to other isolates of the same species [2, 10]. Therefore, microbiological breakpoints distinguish isolates that have evolved resistance through mutations or horizontal gene transfer from wild-type isolates, independent of whether the degree of resistance is clinically significant [7]. The current investigation considers wild-type organisms as those with ‘typical’ susceptibility patterns to antibiotics [11]. These would be regarded as those not having acquired resistance genes or genetic changes, making them sensitive to antimicrobial agents [11]. There is a significant knowledge gap and a lack of understanding of the application of the different breakpoints in the literature. In recent literature, clinical and microbiological breakpoints are often used interchangeably [7, 8], leading to confusion and a reduction in the relevance of the research involved. Even though EUCAST (European Committee on Antimicrobial Susceptibility Testing) epidemiological cut-offs (ECOFFs) and CLSI (Clinical & Laboratory Standards Institute) breakpoints strive to strike a balance between clinical relevance (e.g. application of pharmacokinetic/pharmacodynamic principles in establishing the breakpoints) and the need to identify emerging resistance, ECOFFs generally maintain that organisms found in the wild-type distribution (susceptible population) have a low likelihood of clinical treatment failure [12]. This may translate into lower breakpoints for EUCAST ECOFFs compared to CLSI, leading to a broader categorization of isolates as susceptible. Erroneous classification of certain isolates as susceptible based on EUCAST breakpoints could theoretically increase treatment failure rates [13]. Despite lack of consensus in the use of breakpoints in the literature, ECOFFs remain the most widely used breakpoints in microbiological research, while CLSI breakpoints are the standard in clinical settings [7–10]. EUCAST ECOFFs were developed in Europe [7], while CLSI breakpoints were developed in the USA [7, 11], although both breakpoints are now universally acknowledged. Recent research has offered a novel approach for establishing breakpoints that employs normalized resistance interpretations (NRIs) to address the EUCAST ECOFF constraints [12–14]. The method involves entering MIC zone sizes of a set of isolates into a spreadsheet and calculating the distribution, smoothing the distribution using rolling means, identifying the peak of the smoothed distribution and calculating the estimated total number of wild-type (WT) observations [12]. The distribution of percentage, cumulative percentage and probit values of the WT observations are then calculated, and the slope and the intercept of the best-fit line of the probit values versus zone size are determined using a least squares method [12]. The mean and standard deviation of the normalized WT distribution are then calculated, and the epidemiological cut-off values are set at the mean minus 2.5 times the standard deviation [12]. The functional peak serves as a reference point for determining the portion of the distribution that corresponds to WT isolates and contributes to setting cut-off values/breakpoints for resistance interpretation [12]. A functional peak is generally established after a putative peak has been identified and modulated according to protocol conditions stipulated by Kronvall and Smith [12] using the NRI method. However, one major flaw of this method is that it assumes that the WT observations are symmetrically distributed around the peak which may not hold true in all cases [14–16]. Moreover, the accuracy of the NRI method can be influenced by

the size of the dataset used for analysis [12, 14, 16]. Small sample sizes may lead to less precise estimates of the parameters such as the functional peak and standard deviation, potentially affecting the reliability of the interpretation [12, 14, 16]. However, the generated bespoke breakpoints allow for laboratory-specific strain classifications of WT and non-wild-type (NWT) strains [12–14]. The method allows for reconstruction of the normalized peak for MIC or IZD distributions as long as resistance is not developed in the WT population [12, 16]. Tiny variations in zone diameters including low-level resistance in the WT populations can, therefore, be identified even within populations considered primarily susceptible by traditional interpretations (EUCAST and CLSI) [12, 16]. Furthermore, novel forms of resistance can also be detected, increasing antibiotic susceptibility testing sensitivity and precision [13]. By normalizing the data, the technique improves comparability between laboratories and minimizes the effect of variability on resistance interpretation [13]. Consequently, standardization of breakpoints is possible in certain datasets, provided reproducibility and precision are demonstrated [13, 14].

Despite developments in microbiological breakpoints, research into how these breakpoints perform when applied to data from low-income countries is sparse. There is still a dearth of knowledge concerning the validity of prevalence estimates of data from low-income countries employing these breakpoints. EUCAST ECOFFs and CLSI breakpoints are primarily generated with data from developed countries [9]. Moreover, since most of the data used to generate the ECOFF reference distribution are of human origin [9], the underlying breakpoints are unlikely to provide an accurate framework for evaluating data from animals or the environment.

The present study evaluated the prevalence of AMR in four types of poultry farms in Moshi and Arusha, Tanzania, using CLSI breakpoints, ECOFFs, and bespoke thresholds generated from NRIs. The study also aimed to ascertain whether the selected breakpoint has any bearing on resistance prevalence predictions.

## METHODS

### Study design and location

This study was part of a broader prospective cross-sectional study conducted in Arusha and Moshi districts in Tanzania whose aim was to determine whether different poultry husbandry systems were associated with varying degrees of AMR among poultry populations. The initial study collected 746 samples out of a target of 800 from four different farm types, with ten cloacal swabs collected per farm type. These data were collected from selected wards, with ten selected from each district, Arusha and Moshi. In the context of this study, wards refer to administrative subdivisions or smaller geographical areas within the districts of Arusha and Moshi, which are used for local governance and representation. Taking budgetary considerations into account, 74 plate sweeps were shipped to the One Health Research in Bacterial Infectious Diseases (ORHBID) laboratory, located at the Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, for analysis. Of the 74 plate sweeps, 74 isolates which exhibited successful growth following subculture on MacConkey agar were selected for the present study, with each isolate representing each plate.

### Identification of antimicrobial-resistant lactose-fermenting coliforms on MacConkey agar

Using a modified breakpoint plate method described by Caudell [17], we assessed the total population of coliforms and resistant coliforms present on MacConkey agar with and without antimicrobials [15]. Interpretation of resistant coliforms to the selected antimicrobial drugs at defined concentrations was conducted according to CLSI 2016 guidelines. Coliforms formed pink to red colonies, while other lactose-intolerant Gram-negative bacteria formed pale white colonies. Frozen ( $-80^{\circ}\text{C}$ ) cloacal swab samples were thawed overnight at  $2^{\circ}\text{C}$  for isolation. Following homogenization,  $50\ \mu\text{l}$  of each sample was added and vortexed with  $450\ \mu\text{l}$  of maximum recovery diluent (MRD; Oxoid Thermofisher). Plating was performed on plain MacConkey plates without antibiotics and MacConkey plates supplemented with antimicrobial agents using a spiral plater (Spiral System) programmed to dispense  $50\ \mu\text{l}$  of the mixture in a logarithmic dilution. Coliforms were enumerated using the spiral plater grid technique at Kilimanjaro Clinical Research Institute (KCRI) after incubation on plain MacConkey agar and MacConkey agar with antimicrobials. Each plate was mapped with a grid, placed on a level surface and adjusted so that the grid's centre corresponded to the plate's centre on the viewer. Colonies were counted from the outer border of each section into the centre, allowing the bacterial concentration to be estimated.

### Collection and storage of plate sweeps

Coliform bacteria plate sweeps were obtained from plain MacConkey agar plates and subsequently preserved at  $-80^{\circ}\text{C}$ . Two vials of plate sweeps were collected from each plate, with both vials subjected to storage in a preservation medium consisting of MRD media and 15% glycerol. One vial was stored at  $-80^{\circ}\text{C}$  and retained in Tanzania for future reference (archived), while the second vial was temporarily stored at  $-80^{\circ}\text{C}$ , awaiting shipment to the ORHBID laboratory at Glasgow University (aliquot used in the present study). To ensure preservation during transportation, the frozen plate sweeps were shipped using dry ice. The primary objective of this shipment was to facilitate further analysis and investigation at the aforementioned laboratory.

## Phenotypic identification of *Escherichia coli* using chromogenic agar

At the OHRBID laboratory, cloacal swabs were thawed overnight at 2 °C and 50 µl of the sample was homogenized with 450 µl of MRD. The mixture was vortexed, and 50 µl was plated on MacConkey agar with a spiral plater (Spiral System) and incubated at 37 °C. Pink lactose-fermenting colonies were inoculated on Luria-Bertani broth (Oxoid) and incubated at 37 °C for 24 h. Pure culture (50 µl) was inoculated on chromogenic agar (CHROMagar ECC; Sigma Aldrich), spread evenly using a sterile L-shaped spreader (VWR; catalogue number 6121560P) and incubated for 24 h at 37 °C. Phenotypic blue colonies indicated the presence of *E. coli* isolates, and selected isolates were confirmed via quantitative *uidA* PCR as described in the section below on confirmation of *E. coli* species

## Reference strains

As part of this study, reference strains originating from dogs were obtained from the University of Glasgow's Veterinary Diagnostic Services laboratory for subsequent analysis. Identities of the strains were confirmed using API 20E strips (API system by bioMérieux, available at <https://www.biomerieux.co.uk/product/apir-id-strip-range>). A positive *E. coli* control and a negative *Klebsiella* species control were used for both genotypic and phenotypic confirmation of *E. coli* isolates. These two reference isolates were resistant to all antimicrobial agents used in this study.

## Molecular detection of *E. coli* using quantitative *uidA* PCR

### DNA extraction

DNA extraction was conducted using a QIAamp DNA mini-Kit (Qiagen). Isolates from CHROMagar were resuspended in 1 ml Luria-Bertani media (VWR) and 50 µl was processed according to the manufacturer's instructions provided with the QIAamp DNA mini-Kit. DNA concentrations were determined using the NanoDrop (NanoDrop-2000 Spectrophotometer; NanoDrop Technologies).

### Confirmation of *E. coli* species using *uidA* PCR

Real-time quantitative PCR (RTqPCR) was performed using the Rotor gene system (Applied Biosystems) to identify the *uidA* gene, an 1809 bp gene expressed by all *E. coli* bacteria. The *uidA* RTqPCR primers and probe used for detection were as described by Frahm and Obst [16]. The probe was labelled with 56-FAM as a reporter fluorescent dye at the 5' end and the 3' end with BHQ\_1 as the quencher dye. Reactions for *uidA* RTqPCR were performed as described by Frahm and Obst [16]. The RTqPCRs were performed in a 15 µl reaction volume using 2× Quantitect Probe PCR master mix (Qiagen), 0.4 µM of each primer, 0.2 µM of probe (Integrated DNA Technology) and 5 µl of template DNA from presumptive *E. coli* isolates. PCR cycling conditions consisted of an initial denaturation step at 95 °C for 2 min, followed by 45 cycles of denaturation at 95 °C for 5 s and annealing/extension at 60 °C for 5 s.

### Culture and susceptibility testing using disc diffusion test

Antimicrobial susceptibility testing (AST) was conducted using a standardized disc diffusion technique [17]. *E. coli* was tested against four [4] antimicrobial agents at standard disc quantity according to EUCAST recommendations, i.e. ceftazidime (30 µg), ciprofloxacin (5 µl), imipenem (10 µg) and tetracycline (30 µg). The procedure involved diluting the culture suspension with distilled water to a density of 0.5 MacFarland. Mueller Hinton agar was poured in plates (90 mm in diameter, 4–6 mm in depth). Prior to inoculation, the plates were air-dried for about 30 min. Bacterial suspensions at 0.5 MacFarland were streaked evenly across the surface of the medium with a plate spreader (VWR; catalogue number 6121560P). After drying for 3–5 min, the four antimicrobial discs were placed on the agar surface using a sterile forceps and gently pressed down to ensure contact. The plates were incubated at 37 °C under aerobic conditions. After overnight incubation, the zone diameters were measured on the reverse side of the culture plate using a vernier calliper.

### Data analysis

The IZD for each antimicrobial agent tested was assessed using breakpoints, CB, ECOFFs or wild-type bespoke cutoff ( $CO_{WT}$ ) values based on NRI to identify the prevalence of susceptible and resistant isolates. The clinical breakpoints (CBs) were determined using the 2016 CLSI guideline, ECOFFs were generated using EUCAST guidelines [11]. Since ECOFFs for 30 g tetracycline were unavailable on the EUCAST website, the distribution of tigecycline, a member of the same antimicrobial class as tetracycline with the requisite concentration, was substituted for visual comparison purposes. The focus was on comparing the distribution patterns between the current study and the mentioned antimicrobial class reference distributions, in order to assess the similarity or dissimilarity with our data. However, it is important to note that the breakpoint for tigecycline was not used in this analysis to ensure accuracy and avoid potential misinterpretations. All calculations of the  $CO_{WT}$  were conducted according to specifications in a published protocol by Kronvall and Smith [12] using a spreadsheet provided by the authors (European patent No. 1 383 913, US Patent No. 7,465,559; <https://doi.org/10.1111/apm.12624>). The IZD histograms and  $CO_{WT}$  values for each compound were computed using the provided spreadsheet. Additionally, the construction of the functional peak was generated following the steps outlined by Kronvall and Smith [12], utilizing an automated sheet available online at <https://doi.org/10.1111/apm.12624>.

The prevalence of resistance among poultry *E. coli* isolates from Tanzania was calculated using three distinct thresholds: CB, ECOFFs and CO<sub>WT</sub>.

## RESULTS

### Phenotypic and molecular detection of *E. coli*

Out of 74 plate sweeps that were shipped to the University of Glasgow for further analysis and subsequently cultured on MacConkey agar, a total of 74 isolates (one isolate per plate sweep) were successfully cultivated. Following subculture on CHROMagar from MacConkey agar, 72 isolates displayed blue colonies, indicating a presumptive identification as *E. coli*. However, subsequent confirmation using *uidA* PCR revealed that out of these 72 isolates, 59 were confirmed to be *E. coli* (data available in Table S1: Molecular\_Phenotypic\_results, available in the online version of this article).

### Susceptibility testing

In line with the objective of the current study, which seeks to compare resistance interpretation based on three breakpoints, we began by visualizing the range of IZD values collected per antimicrobial as seen in Tables 1 and S1: Distributions. For each antimicrobial class, there was at least one isolate that exhibited a zone diameter of 6 mm. Following that, the distribution of IZD values was examined using the NRI approach and visualized across all antimicrobial classes, as illustrated in Fig. 1. The approach allowed the determination of the mean zone size and standard deviation (SD) for WT isolates, as well as CO<sub>WT</sub> for each compound, as depicted in Table 1 and normalized histograms in Fig. 2. The estimated SD values for ciprofloxacin, imipenem and ceftazidime IZDs exceeded the recommended limit of 4 mm [18], except for tetracycline (Table 1).

### Comparison of EUCAST reference data and Tanzanian poultry data

The distribution of IZD values for *E. coli* isolates (Table S1: Distributions) obtained from poultry in Tanzania showed a noticeable shift towards lower IZD values across all antimicrobial agents tested. This shift in values, as illustrated in Fig. 1, indicates reduced susceptibility levels compared to the reference data provided by EUCAST. Specifically, the CB for tetracycline was lower than the CO<sub>WT</sub>. While the clinical breakpoints deviated from the CO<sub>WT</sub> by 5 mm or less for all compounds, the ECOFFs were significantly higher than the corresponding CO<sub>WT</sub> values. The wild type cut-offs (CO<sub>WT</sub>) were lower than CB and ECOFFs for all antimicrobials except tetracycline (Fig. 1).

### Estimation of the prevalence of AMR in *E. coli* from Tanzanian poultry based on ECOFFs, CB and CO<sub>WT</sub>


There was no statistically significant difference in the prevalence estimates of ceftazidime, imipenem, ciprofloxacin and tetracycline resistance when interpretation was conducted using the CO<sub>WT</sub> cut-off and clinical breakpoints (CB) ( $\chi^2=1.29$ , d.f.=3,  $P>0.05$ ). However, when comparison of the interpretations of the ECOFFs with the other two breakpoints was conducted, a significantly higher prevalence of resistance was observed for ECOFF values, except for tetracycline where breakpoint values were unavailable for the desired concentration. This difference was statistically significant, as presented in Table 2 ( $\chi^2=23.91$ , d.f.=4,  $P<0.05$ ). The proportions of susceptible isolates determined by CB, CO<sub>WT</sub> and ECOFF values were not significantly different ( $\chi^2=2.830$ , d.f.=4,  $P>0.05$ ) for CEF, CIPRO and IMI, as presented in Table 2.

## DISCUSSION


The aim of this study was to examine whether AMR estimates varied depending on the AMR breakpoint used. In contrast to clinical breakpoints, which define resistance as the likelihood of treatment failure, epidemiological cut-offs and bespoke normalized resistance interpretive breakpoints use microbiological criteria to define resistance [2, 8, 10]. Previous studies have used these breakpoints to interpret resistance [6–20]. The current study compared prevalence estimates of resistant *E. coli* isolates based on the epidemiological cut-offs (ECOFFs), CLSI break-points (CBs) and NRI bespoke breakpoints (CO<sub>WT</sub>). Prevalence estimates of ceftazidime, imipenem and tetracycline resistance based on CO<sub>WT</sub> and CB did not differ significantly; however, ECOFF values

**Table 1.** The functional peak, standard deviation of the functional peak and cut-off values for WT were observed in a range of inhibition zone diameters and output by normalized resistance interpretation (CO<sub>WT</sub>)

| Antimicrobial | Range (mm) | Functional peak (mm) | SD (mm) | CO <sub>WT</sub> (mm) |
|---------------|------------|----------------------|---------|-----------------------|
| Ceftazidime   | 6–38       | 29.0                 | 4.8     | 15                    |
| Ciprofloxacin | 6–40       | 26.5                 | 5.1     | 14                    |
| Imipenem      | 6–38       | 24.5                 | 4.7     | 13                    |
| Tetracycline  | 6–21       | 18.0                 | 2.1     | 14                    |



**Fig. 1.** Distribution of inhibition zone diameters (IZDs) produced by 30 µg ceftazidime, 5 µg ciprofloxacin, 10 µg imipenem or 30 µg tetracycline discs against *Escherichia coli*. The coloured bars indicate results for *E. coli* from poultry cloacal swabs from Tanzania ( $n=59$ ). The distribution of IZDs from *E. coli* isolates from EUCAST data is shown in black bars [ $n=11\ 875, 36\ 774, 4600$  and  $326$  for ceftazidime (CEF), ciprofloxacin (CIPRO), imipenem (IMI) and tetracycline (TET), respectively]. Dashed lines represent CB (blue), ECOFFs (red; not available for TET) and  $CO_{WT}$  (black) based on normalized resistance interpretation of the data from Tanzanian poultry. Data used in plotting the distribution graphs can be found in Table S1: Distributions.



**Fig. 2.** Bar graphs illustrating the inhibitory zones formed by discs containing 30 g ceftazidime, 5 g ciprofloxacin, 10 g imipenem or 30 g tetracycline. The four-point rolling mean is represented by the continuous black curve, while the wild-type cutoff ( $CO_{WT}$ ) is generated from the data using the normalized resistance interpretation method. Graphs were prepared in Microsoft Excel, using the spreadsheet provided by P. Smith, W. Finnegan, and G. Kronvall (European patent No. 1383913, US Patent No. 7,465,559).

**Table 2.** The proportion of resistant (R), non-wild-type (NWT), susceptible (S) or wild-type (WT) *Escherichia coli* isolates from poultry cloacal samples from Tanzania determined by CB, ECOFFs and the CO<sub>WT</sub> according to normalized resistance interpretation

| Antimicrobial | CB | S (%) | R (%) | ECOFF (mm) | WT (%) | R (%) | CO <sub>WT</sub> (mm) | WT (%) | NWT (%) |
|---------------|----|-------|-------|------------|--------|-------|-----------------------|--------|---------|
| Ceftazidime   | 17 | 98.3  | 1.7   | 24         | 54.2   | 45.8  | 15                    | 98.3   | 1.7     |
| Ciprofloxacin | 19 | 67.8  | 32.2  | 25         | 35.6   | 64.4  | 14                    | 81.4   | 18.6    |
| Imipenem      | 15 | 96.6  | 3.4   | 24         | 64.4   | 35.6  | 13                    | 96.0   | 4.0     |
| Tetracycline  | 11 | 32.2  | 67.8  | –          | –      | –     | 14                    | 30.5   | 69.5    |

for ceftazidime and imipenem resistance were significantly higher. Ciprofloxacin resistance varied significantly across all three breakpoints. However, ECOFFs generated the highest prevalence estimates of ciprofloxacin resistance, followed by CB, and the lowest estimates were generated by CO<sub>WT</sub>. Finding resistance to carbapenem (imipenem), third-generation cephalosporin (ceftazidime) and fluoroquinolone (ciprofloxacin) in poultry is alarming as these antimicrobials are listed as World Health Organisation (WHO) Critically Important Antimicrobials. Third-generation cephalosporins are designated as Highest Priority Critically Important Antimicrobials (HP CIAs) [20]. Additionally, carbapenems and third-generation cephalosporins are rarely used in livestock production in Tanzania [21, 22], making their resistance presence a cause for concern.

Clinical breakpoints (CB) and CO<sub>WT</sub> breakpoints did not differ significantly in their interpretations of resistance to antimicrobial agents, especially for ceftazidime, imipenem and tetracyclines, an observation that differs from the observations of Dias *et al.* [18, 23], where AMR prevalence estimates varied according to the thresholds used [18]. NRI may, however, interpret values as susceptible if (low-level) resistance is prevalent in a dataset [13]. Furthermore, the NRI method has a fundamental flaw in that cutoffs generated from small datasets may not be accurate or representative of a larger population [18]. For instance, three antimicrobials in our data exceeded the allowable standard deviation [18], which necessitates caution when interpreting the results of our study. Small datasets are more susceptible to outliers and random variation, which can lead to high SD values and high variability in NRI results [18]. The present study used a small dataset. As a result, meaningful trends and accurate interpretations are constrained. Additionally, there were several distributions in our study that were bimodal rather than unimodal. Since the NRI technique estimates CO<sub>WT</sub> values based on the distribution's highest peak assuming a normal distribution, the significance of the second peak on lower IZD scores is likely to be overlooked, despite it indicating the presence of an intermediate population. To fully understand this phenomenon, larger datasets are needed [11, 24].

The prevalence of tetracycline resistance based on the current dataset was higher than that of other antimicrobials, while ceftazidime and imipenem resistance were low, and ciprofloxacin resistance was moderate. The results were consistent with previous research conducted in the northern part of Tanzania where similar occurrences of tetracycline resistance were found [21, 22, 25]. One of the underlying driving factors is the widespread use of tetracycline in poultry production in northern Tanzania [26, 27]. On the other hand, ECOFF and CB predicted higher estimates of AMR compared to CO<sub>WT</sub>. However, our findings do not align with previous studies conducted in the same districts. Discrepancies may have arisen due to different methodologies used. Contrary to our finding, Hamis *et al.* [22, 28] used both the Kirby–Bauer method and clinical breakpoints and found a significantly higher prevalence of ciprofloxacin resistance. Rugumisa *et al.* [25, 29] used the breakpoint plate method and clinical breakpoints and found lower rates of ciprofloxacin resistance. As our study and the referred studies were conducted on different poultry populations, the results may also indicate that ciprofloxacin resistance varies by population.

Resistance to imipenem and ceftazidime were observed in poultry *E. coli* isolates. However, these agents are rarely used in poultry production in Arusha, according to a qualitative survey on antimicrobial use published by Sindiyo *et al.* in 2018 [26]. Consequently, it was not anticipated that this population would be resistant to these antimicrobials. Nonetheless, other studies in the same districts revealed the presence of isolates resistant to third-generation cephalosporins in poultry. For example, Hamisi *et al.* [22, 28] found 29.8% of poultry isolates were resistant to cefotaxime, whereas Rugumisa *et al.* [25, 29] observed a lower prevalence of ceftazidime resistance. Although the presence of imipenem and ceftazidime on farms is unlikely to be associated with their direct use in poultry, our results suggest that bacteria resistant to these antibiotics can be found in other local reservoirs [26]. Bacteria with *bla*TEM and *bla*CTX-M79 genes have been reported in closed (i.e. tap water) and open water sources in the northern part of Tanzania, indicating the existence of alternative AMR bacteria reservoirs in lakes and rivers [26]. Considering most farmers in the northern zone of Tanzania use tap water for poultry production, the presence of *bla*TEM genes and *bla*CTX-M79 in tap water may explain ceftazidime resistance in *E. coli* isolates from animals that were not exposed to antimicrobials [26]. Prior to this study, no research into imipenem resistance in poultry had been conducted in Tanzania. As a result, no direct evidence could be found indicating the origins of imipenem resistance in poultry. Despite restrictions on imipenem usage in Tanzania, informal use may occur due to limited regulatory enforcement and access to antibiotics [30]. This informal practice can be driven by factors such as antibiotic availability without a prescription, self-medication culture and economic considerations in the poultry industry [30]. Animals can also acquire imipenem-resistant *E. coli* from humans via faeces if they are exposed to human excrement [28].



In the current study, poultry-derived isolates had smaller zone sizes than EUCAST reference isolates and were subsequently classified as resistant based on EUCAST thresholds. This highlights the potential for misclassification of a portion of poultry isolates from the normal distribution as resistant, according to the EUCAST reference distributions, and ECOFFS (which are primarily derived from human-centric datasets). Similar shifts have been observed when comparing EUCAST data to Gram-negative isolates from animals [18]. Humans and animals have inherent variability, which may explain why WT distributions considered normal in animals may not be normal in humans. Animals, including ruminants and other herbivores, have more complex digestive tracts than humans [30, 31, 32]. One key factor contributing to this variation is largely due to the diversity of microbes in the animal gut versus that of humans [33, 34]. The animal gut contains a wider variety of microbes that contribute to metabolic processes and nutrient breakdown [33, 34]. The pH of the gut, nutritional availability, diet and interactions with host factors can influence bacterial proliferation, including those that harbour antibiotic resistance genes [35]. In agricultural and veterinary settings, animals are often exposed to antimicrobial agents for therapeutic purposes, growth promotion or prophylaxis [30]. In the presence of this selective pressure, resistance to antimicrobials, including resistance caused by efflux pumps, can develop and spread. Furthermore, varying antimicrobial use patterns can contribute to differences in resistance profiles, as well as efflux pump expression. According to recent research, upregulated efflux pumps have been found to be prevalent in animals compared to humans [31]. The AcrAB-TolC efflux pump system, for instance, has been linked to multidrug resistance and frequently is upregulated in animal-associated bacteria, such as poultry [36]. On the other hand, the MexXY-OprM efflux pump system, which is frequently found in *Pseudomonas aeruginosa*, confers resistance to many antimicrobials, including fluoroquinolones and aminoglycosides, and has been observed to be highly expressed in animal-associated strains [37]. Contrary to the underlying evidence supporting IZD variation, Sjölund *et al.* [38] found similar distributions between human and poultry isolates, despite poultry-derived isolates being collected from environments without antimicrobial exposure, thus suggesting that the two populations have similar WT (wild) populations. In contrast to what was found in this study, Sjölund *et al.* [38] revealed that wild-type bird isolates exhibited similar distributions to human isolates, despite being collected from birds in pristine environments with little exposure to antimicrobial agents [38]. Nevertheless, other reasons that may explain variations and discrepancies may have been attributed to methodology in these studies, despite systematic efforts to standardize procedures [12]. Furthermore, EUCAST distributions are inherently known to originate from data generated by different sources [39]. Our observations, however, may be an artefact of the resistance mechanisms that might have developed as a result of antimicrobial exposure, and hence the shift to lower zones of inhibition.

Our study acknowledges the potential bias introduced by selecting microbes based on a single breakpoint at the beginning of our analysis where we implemented a screening approach using McConkey agar with and without antibiotics, categorizing isolates that grew on media with antibiotics as resistant. We recognize that including the three breakpoints would have provided a more comprehensive assessment of the impact of different breakpoints on resistance classification. However, due to technical limitations, we were unable to incorporate that at the beginning of our study. Despite this limitation, our study still provides valuable insights by focusing on the comparison of specific breakpoints and their implications in resistance classification. By investigating these selected breakpoints, we shed light on their specific characteristics and provide meaningful insights within the defined scope of our study

## CONCLUSION

This study illustrates how different thresholds can impact the interpretation of resistance. ECOFFs or CB thresholds may overestimate [40] or underestimate prevalence when used instead of bespoke thresholds. EUCAST is largely composed of the human-centric datasets SENTRY and MYSTIC, with little representation of African and animal data. As a consequence, the EUCAST dataset does not accurately portray the WT distribution of human or poultry *E. coli* isolates from Africa. Additionally, clinical breakpoints are developed for human therapeutic purposes, but the same breakpoints are applied to interpret information from various animal studies. Considering limitations of datasets used to generate the thresholds, it is uncertain whether the existing threshold schemes are true universal reference metrics for resistance interpretation, since they may lead to misinterpretations of resistance, particularly in low-income countries. It is important to re-examine the current thresholds and include data from low-resource countries to make the thresholds more inclusive.

---

### Funding information

This project was funded by a grant from the Biotechnology and Biological Sciences Research Council (BBSRC), Zoonoses and Emerging Livestock Systems (ZELS), University of Glasgow College of Medical, Veterinary and Life Sciences, Kilimanjaro Clinical Research Institute, and Nelson Mandela African Institute of Science and Technology (NM-AIST).

### Acknowledgements

The authors would like to thank all members of the University of Glasgow Research into Bacteria Infectious Diseases (ORHBID) laboratory for their contributions. The authors wish to acknowledge also the zoonosis lab at the Kilimanjaro Research Institute, as well as its director, Professor Blandina Mmbaga. Thanks are also due to the research assistants and technicians who assisted with sample analysis.

**Author contributions**

R.M., E.S., G.S., B.T.M., L.M. and R.Z. were all involved in the project's conceptualization and design. R.M. and E.S. performed the sample collection, laboratory experiments and data analysis. R.M. and V.M.M. prepared the manuscript. All the authors read and approved the final manuscript.

**Conflicts of interest**

The authors declare no competing interest.

**Ethical statement**

Ethical approval for this work was granted by the National Institute for Medical Research (NIMR/HQ/R.8a/Vol.IX/2028) and the Kilimanjaro Christian Medical Centre (Research Ethical Certificate No. 832), as part of the Zoonoses and Emerging Livestock Systems project. Poultry sampling was approved by the University of Glasgow School of Veterinary Medicine Research Ethics Committee (Ref. 56 a/16). A letter of approval was provided by the Municipal Council of Arusha Urban District, where the research took place.

**References**

1. Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: a global emerging threat to public health systems. *Crit Rev Food Sci Nutr* 2017;57:2857–2876.
2. van Belkum A, Burnham C-AD, Rossen JWA, Mallard F, Rochas O, et al. Innovative and rapid antimicrobial susceptibility testing systems. *Nat Rev Microbiol* 2020;18:299–311.
3. Anjum MF, Zankari E, Hasman H. Molecular methods for detection of antimicrobial resistance. *Microbiol Spectr* 2017;5.
4. Lambert RJW, Pearson J. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. *J Appl Microbiol* 2000;88:784–790.
5. Barry AL, Coyle MB, Thornsberry C, Gerlach EH, Hawkinson RW. Methods of measuring zones of inhibition with the Bauer-Kirby disk susceptibility test. *J Clin Microbiol* 1979;10:885–889.
6. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. *Clin Microbiol Rev* 2007;20:391–408.
7. Kahlmeter G, Brown DFJ, Goldstein FW, MacGowan AP, Mouton JW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. *J Antimicrob Chemother* 2003;52:145–148.
8. Fazal F. European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute breakpoints—the only point that matters in candidemia? *J Thorac Dis* 2019;11:S1412–S1414.
9. Macgowan AP, BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. *J Antimicrob Chemother* 2008;62 Suppl 2:ii105–14.
10. Humphries RM, Abbott AN, Hindler JA, Kraft CS. Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. *J Clin Microbiol* 2019;57:1–15.
11. Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, et al. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. *Clin Microbiol Infect* 2017;23:2–22.
12. Kronvall Göran, Smith P. Normalized resistance interpretation, the NRI method. *APMIS* 2016;124:1023–1030.
13. Espinel-Ingroff A, Turnidge J. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. *Rev Iberoam Micol* 2016;33:63–75.
14. Kronvall G, Giske CG, Kahlmeter G, Kronvall G, Giske CG. Setting interpretive breakpoints for antimicrobial susceptibility testing using disk diffusion. *Int J Antimicrob Agents* 2011;38:281–290.
15. Kronvall G, Smith P. Normalized resistance interpretation, the NRI method: review of NRI disc test applications and guide to calculations. *APMIS* 2016;124:1023–1030.
16. Kronvall G. Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints. *J Clin Microbiol* 2010;48:4445–4452.
17. Caudell MA, Mair C, Subbiah M, Matthews L, Quinlan RJ, et al. Identification of risk factors associated with carriage of resistant *Escherichia coli* in three culturally diverse ethnic groups in Tanzania: a biological and socioeconomic analysis. *Lancet Planet Heal* 2018;2:e489–e497.
18. Smith P, Schwarz T, Verner-Jeffreys DW. Use of normalised resistance analyses to set interpretive criteria for antibiotic disc diffusion data produce by *Aeromonas* spp. *Aquaculture* 2012;326–329:27–35.
19. Frahm E, Obst U. Application of the fluorogenic probe technique (TaqMan PCR) to the detection of *Enterococcus* spp. and *Escherichia coli* in water samples. *J Microbiol Methods* 2003;52:123–131.
20. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 1966;45:493–496.
21. Bernadether TR, Douglas RC, Gaspary OM, Murugan S, Joram B. Comparison of the prevalence of antibiotic-resistant *Escherichia coli* isolates from commercial-layer and free-range chickens in Arusha district, Tanzania. *Afr J Microbiol Res* 2016;10:1422–1429.
22. WHO. WHO | World Health Statistics 2017: Monitoring health for the SDGs. World Health Organization; 2017. [https://www.who.int/gho/publications/world\\_health\\_statistics/2017/en/](https://www.who.int/gho/publications/world_health_statistics/2017/en/) [accessed 28 April 2019].
23. Dias D, Torres RT, Kronvall G, Fonseca C, Mendo S, et al. Assessment of antibiotic resistance of *Escherichia coli* isolates and screening of *Salmonella* spp. in wild ungulates from Portugal. *Res Microbiol* 2015;166:584–593.
24. Smith Peter, Christoflogiannis P. Application of Normalised Resistance Interpretation to the detection of multiple low-level resistance in strains of *Vibrio anguillarum* obtained from Greek fish farms. *Aquaculture* 2007;272:223–230.
25. Kimera ZI, Frumence G, Mboera LEG, Rweyemamu M, Mshana SE, et al. Assessment of drivers of antimicrobial use and resistance in poultry and domestic pig farming in the Msimbazi River Basin in Tanzania. *Antibiotics* 2020;9:838.
26. Sindiyo E, Maganga R, Thomas K, Benschop J, Swai E, et al. Food Safety, Health Management, and Biosecurity Characteristics of Poultry Farms in Arusha City, Northern Tanzania, Along a Gradient of Intensification. *EAHRJ* 2018;2:168–180.
27. Caudell MA, Quinlan MB, Subbiah Murugan, Call DR, Roulette CJ, et al. Antimicrobial use and veterinary care among agro-pastoralists in Northern Tanzania. *PLoS One* 2017;12:e0170328.
28. Hamisi Z, Tuntufye H, Shahada F, Hamisi Z, Tuntufye H, et al. Antimicrobial resistance phenotypes of *Escherichia coli* isolated from tropical free range chickens. *Int J Sci Res* 2014;3.
29. Rugumisa BT, Call DR, Mwanjika GO, Mrutu RI, Luanda CM, et al. Prevalence of antibiotic-resistant fecal *Escherichia coli* isolates from penned broiler and scavenging local chickens in Arusha, Tanzania. *J Food Prot* 2016;79:1424–1429.
30. Mdegela RH, Mwakapeje ER, Rubegwa B, Gebeyehu DT, Niyigena S, et al. Antimicrobial use, residues, resistance and governance in the food and agriculture sectors, Tanzania. *Antibiotics* 2021;10:454.
31. Katale BZ, Misinzo G, Mshana SE, Chiyangi H, Campino S, et al. Genetic diversity and risk factors for the transmission of antimicrobial resistance across human, animals and environmental compartments in East Africa: a review. *Antimicrob Resist Infect Control* 2020;9:127.
32. Stevens CE, Hume ID. Contributions of microbes in vertebrate gastrointestinal tract to production and conservation of nutrients. *Physiol Rev* 1998;78:393–427.

33. Xiao S-S, Mi J-D, Mei L, Liang J, Feng K-X, et al. Microbial diversity and community variation in the intestines of layer chickens. *Animals* 2021;11:840.
34. Stanley D, Hughes RJ, Moore RJ. Microbiota of the chicken gastrointestinal tract: influence on health, productivity and disease. *Appl Microbiol Biotechnol* 2014;98:4301–4310.
35. Pan D, Yu Z. Intestinal microbiome of poultry and its interaction with host and diet. *Gut Microbes* 2014;5:108–119.
36. Sato T, Yokota S, Okubo T, Ishihara K, Ueno H, et al. Contribution of the AcrAB-TolC efflux pump to high-level fluoroquinolone resistance in *Escherichia coli* isolated from dogs and humans. *J Vet Med Sci* 2013;75:407–414.
37. Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, et al. Resistance and virulence of *Pseudomonas aeruginosa* clinical strains overproducing the MexCD-OprJ efflux pump. *Antimicrob Agents Chemother* 2008;52:2455–2462.
38. Sjölund M, Bengtsson S, Bonnedahl J, Hernandez J, Olsen B, et al. Antimicrobial susceptibility in *Escherichia coli* of human and avian origin—a comparison of wild-type distributions. *Clin Microbiol Infect* 2009;15:461–465.
39. Copitch JL, Whitehead RN, Webber MA. Prevalence of decreased susceptibility to triclosan in *Salmonella enterica* isolates from animals and humans and association with multiple drug resistance. *Int J Antimicrob Agents* 2010;36:247–251.
40. Cusack TP, Ashley EA, Ling CL, Rattanavong S, Roberts T, et al. Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance. *Clin Microbiol Infect* 2019;25:910–911.

#### Five reasons to publish your next article with a Microbiology Society journal

1. When you submit to our journals, you are supporting Society activities for your community.
2. Experience a fair, transparent process and critical, constructive review.
3. If you are at a Publish and Read institution, you'll enjoy the benefits of Open Access across our journal portfolio.
4. Author feedback says our Editors are 'thorough and fair' and 'patient and caring'.
5. Increase your reach and impact and share your research more widely.

Find out more and submit your article at [microbiologyresearch.org](https://microbiologyresearch.org).

## Peer review history

---

### VERSION 3

---

#### Editor recommendation and comments

<https://doi.org/10.1099/acmi.0.000540.v3.1>

© 2023 de Dios R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License.

**Rubén de Dios**; Brunel University London, Life Sciences, UNITED KINGDOM

Date report received: 13 June 2023

Recommendation: Accept

**Comments:** Thank you very much for your efforts in applying all suggestions and comments to the manuscript. This work is now suitable for publication. Congratulations!

---

#### Author response to reviewers to Version 2

##### Updated feedback and responses

**Dear Editor,**

Thank you very much for your helpful feedback. In line with the suggestions, I have made changes and added my comments.

Please review the use of italics throughout the manuscript as some are missing (e.g. gene names such as *uidA* and the *et al.* abbreviation on the citations need italics)

I have made the changes accordingly.

The comment of reviewer 2 on the differences between the archived and the stocked samples is still not addressed, and the statement is a bit confusing. Please clarify.

I have edited the text to make it clearer (L186-L193). I have stated that vials that were archived were the ones retained in Tanzania. Both the vial used in the current study and the one archived were put into tubes with MRD media and 15% glycerol.

Supplementary tables have been provided, but they are not named appropriately following the platform's guidelines. Furthermore, they are not cited in the results section where it could help the reader's understanding. Also, please provide a Table Legend within the spreadsheets.

I am struggling to find guidance on the naming convention. I have added a combined supplementary Table S1 and updated the names to be more sensible. I have made references to the tables in the manuscript text, and I have included the table legend within the first sheet of the supplementary sheet (S1). Cited in L 269 and L299

Please cite supplementary material sheet 2 in the main manuscript text.

The supplementary material sheet 2 is now cited in lines L274, L285, and L299.

---

### VERSION 2

---

#### Editor recommendation and comments

<https://doi.org/10.1099/acmi.0.000540.v2.1>

© 2023 de Dios R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License.

**Rubén de Dios**; Brunel University London, Life Sciences, UNITED KINGDOM

Date report received: 27 May 2023

Recommendation: Minor Amendment

**Comments:** Thank you very much for your efforts in including all the reviewers suggestions, the manuscript has undoubtedly improved in quality. However, there some changes that still need to be address: ·Please review the use of italics throughout the manuscript as some are missing (e.g. gene names such as uidA and the et al. abbreviation on the citations need italics) ·The comment of reviewer 2 on the differences between the archived and the stocked samples is still not addressed and the statement is a bit confusing. Please clarify. ·Supplementary tables have been provided, but they are not named appropriately following the platform's guidelines. Furthermore, they are not cited in the results section where it could help the reader's understanding. Also, please provide a Table Legend within the spreadsheets.

---

### **Author response to reviewers to Version 1**

**Dear Editor,**

Thank you for considering this manuscript for review, and thank you to the reviewers for their helpful feedback. I have taken most of their kind words onboard and having made their suggested changes, I believe the manuscript is now stronger.

I have taken the liberty of copying the reviewer's specific comments below and responding inline in a red font.

Many thanks,

Ruth Maganga *et al.*

Reviewer 1:

Specific comments

L78: in microbiology, usually a wild type is a strain as it is found in nature, no matter what phenotype or genotype it has. Here, this concept is different, but would only be explained several lines below. I would tackle this distinction at this point, or else it might confuse some readers. (addressed in line 83 - added)

L82-85: this sentence seems to imply that the EUCAST standards do not have clinical applicability at all. More clarity is needed here. – done

L86: change "the Europe" by "Europe". – done

L89: At this point, please give a clear explanation of how the NRI method works and its applicability. As it is explained, it seems very limited and the results might not be comparable to other samples/laboratories/regions.- I have now clarified this in the manuscript (ln 100-108)

L90: here the authors mention a distinction between WT and NWT. However, this definition is still different from the general use of this expression in microbiology. (Please clarify) – done

L105: change "current" to "present". - done

L118: where in Glasgow and which analyses where performed there? Changed – ln 152

L123: I assume "Caudell" refers to reference 15, however this is not in the reference list.- I will come back to this – This has been amended now

L125: if coliforms were assessed as resistant according to CLSI standards, would this not be biased according to this work? I suggest that the authors give a justification for this or at least a reflection

We appreciate the reviewer's concern regarding the potential bias introduced by selecting microbes based on only one specific breakpoint at the beginning of our analysis. We acknowledge that including the three breakpoints would have provided a more comprehensive assessment of the impact of different breakpoints on resistance classification. However, due to technical limitations, we did not include that in our study at the beginning. We believe that despite this limitation, our study still contributes valuable insights by focusing on the comparison of specific breakpoints and their implications in resistance classification. While our findings may not capture the full spectrum of resistance profiles across all breakpoints, they shed light on the specific breakpoints investigated and provide meaningful insights within the scope of our study. We have highlighted this limitation in the discussion section to ensure transparency and encourage future research to address this gap by considering a broader range of breakpoints. We hope that our study's contribution in evaluating and comparing the selected breakpoints will be valuable in advancing the

understanding of resistance interpretation. We appreciate the reviewer's feedback and will ensure that these limitations and their potential impact are duly acknowledged and discussed in the revised manuscript.

L133: Please clarify where each experiment was performed.- I have now clarified this

L137: Please explain the standardised protocol for the sake of reproducibility.- This has now been added

L145-149: was this performed in the same experimental batch as in the previous section? Either way, if the methodology is the same, the authors can refer to that section rather than repeating. -I am not sure I understand your question, because all of the samples were processed in Tanzania to find lactose fermenters and resistant strains, while in the second screening in Glasgow was to find *E. coli* specifically in the mentioned section. So I was highlighting what was done in Glasgow

L153: Please explain the standardised protocol for the sake of reproducibility. - This has been added

L167-173: why use this method rather than 16S rRNA sequencing? – We didn't do this for budgetary constraints

L191: tigecycline belongs to the same antibiotic family as tetracycline, but it is not analogous to it. Please justify why the authors consider appropriate substituting one for the other.

Thank you for your valuable input. We have carefully reviewed your comments and have made the necessary adjustments to address the concern you raised. In the manuscript, we have included the following statement to justify our approach:

"Since ECOFFs for 30g tetracycline were unavailable on the EUCAST website, the distribution of tigecycline, a member of the same antimicrobial class as tetracycline with the requisite concentration, was substituted for visual comparison purposes. The focus of our analysis was on comparing the distribution patterns between the current study and the reference distributions of the mentioned antimicrobial class. This allowed us to assess the similarity or dissimilarity between our data and the established reference distributions. It is important to note that the breakpoint for tigecycline was not utilized in this analysis to ensure accuracy and avoid potential misinterpretations."

By incorporating this clarification in the manuscript, we aim to provide transparency regarding our choice of substitution and emphasize our commitment to accuracy in our analysis. We appreciate your guidance and believe that these amendments strengthen the scientific rigor of our study.

L207: Are the different isolates individually labelled/barcoded? As they are mentioned, the reader cannot know which of them correspond to each result. This information must be made available. – This will be available as ESI alongside the manuscript.

L211: Figure 1 is not cited in the text. Furthermore, it merely shows a calibration curve. It would much more appropriate to show the actual qPCR results compared to a negative and positive control.- I have removed this image as suggested.

L215-216: This is a clear example of the need to improve clarity. The sentence "In at least one antimicrobial, there was one isolate with a 6 mm zone diameter". These sentence does not offer any information and, as there is no individualised information of the isolates, the reader cannot be able to track it. Also, to the best of my knowledge, 6-7 mm is the usual size of the antibiotic discs used for disc diffusiojob seen assays. Does this mean this grew to the edge of the disc? – This has now been clarified.

L220: does this issue with the SD mean the results are not reliable? – yes if the dataset is small

L225: what is the functional peak? – A description of this is now in the introduction

L237: how would this compare to the CLSI breakpoints? – we have provided a description in the introduction and discussion section

L251: what is the prevalence estimate for cipro? – thanks for highlighting this. we have added this information

L253: previously, the authors had mentioned that they would consider breakpoints for tigecycline as they are not available for tetracycline. However, here the authors consider all breakpoints except the one for tetracycline as it is not available. Please clarify this.- We have now clarified this in the method section, we do not use it for any of the analysis, only for visual comparison of the distributions as explained above.

L272: here ECOFFS should be CLSI breakpoint?- amended to CLSI accordingly

L285-286: here the authors reach the idea that NRI interpretation might be affected by the dataset. Can the authors elaborate on how the application of this method can contribute to standardisation? – I have provided details in the introduction (ln 100)

L294-295: speaking of prevalence, the authors consider it high, low or moderate with respect to what? – We have rephrased this for clarity (ln 336-340)

L323: I have my doubts that imipenem can be used informally. As a last resort antibiotic, not only it is restricted, but also rather expensive in comparison to other antibiotics. Anyway, can the authors give a reason why they think this antibiotic is informally

used? Would there be any alternative explanation? – added information and context (ln 377-382) There is minimal regulatory oversight, and imipenem resistance is found in other livestock and environmental reservoirs.

L327-330: this sentence confuses me. According to my interpretation of Figure 3, all CB and COWT values are below the ECOFFS threshold, making them more restrictive in the definition of a resistant isolate. Can the authors clarify how those isolates could be misclassified as resistant according to ECOFFS in comparison to the other standards? I have clarified this in the text. If the thresholds for CLSI (Clinical and Laboratory Standards Institute) and NRI (Non-Reference Interpretive) criteria are smaller or more stringent than the ECOFFs (Epidemiological Cut-Off Values), it means that ECOFFs would classify a larger number of strains as resistant compared to the other criteria.

L332-333: The authors should elaborate more on how the differences between the human and ruminant digestive tract relate to this study. - We have expanded on this now (ln 390-400)

L334: hyperefflux and antibiotic resistance are widely known to be linked. There are many more recent works in the literature the authors can refer to give a more comprehensive view of this. We have added this in the discussion with literature

L334-338: the authors mention differences in the resistance prevalence in birds from pristine environments with respect to the results of this work, obtained from farm chickens, and justify it by methodological discrepancies. To me, it is very obvious that those two sample groups were not expected to give similar results, and that differences might be affected by the methodology, but I do not think that is the main cause of the discrepancies between these two particular studies.

I think you have misunderstood us in this section. Our intention in this section was to discuss the differences between ECOFF distributions in animals and humans. We aimed to emphasise that the distribution of resistance in animals is expected to differ from the distribution observed in human-derived isolates, since ECOFF distributions are predominantly derived from human data. We referenced a study here to highlight that there is evidence suggesting similarities between bird isolates collected from pristine environments and human isolates, contrary to what one might expect. We agree methodological discrepancies are not the only reason.

Reviewer 2:

Line 86: remove 'the' before Europe – Done

Line 117: what is meant by 'wards' here? I only know this term in a hospital context so please clarify. Also not clear if there are 10 wards total, or 10 for each district (presume the latter as this adds up to 800 total but please clarify). – In the Tanzanian context, wards are smaller divisions within city districts. We have clarified this and the number within the methodology.

Lines 127 and 330: change gram to Gram- Done

Line 130: clarify what is meant by 'plain' plates – Done

Line 140/141: what is meant by 'one vial is archived' as opposed to 'the other preserved at -80 in glycerol'? What does the archiving entail? – vial archived here meant we had to aliquots one which was saved in the -80 freezer and the other used for analysis

The results section lacks clarity. What isolates are used in the susceptibility testing in Table 1 and Fig. 2? Does this refer to the E. coli positive control? If so please indicate. We have clarified in the text and added ESI that addresses this.

Line 215/216: "In at least one antimicrobial, there was one isolate with a 6mm zone diameter". What do the authors mean? According to Fig. 2 there is at least one isolate with 6mm zone for each of the 4 tested antimicrobials. – This has now been clarified.

Line 216/217: "Except for tetracycline, the wild type cut-off (COWT) was lower than CB and ECOFFs". Where can I see this? Or if not visualized, please put between brackets the actual CB and ECOFFs values. This has now been clarified in the text and is visible in figure 2.

Table 1: please indicate how the functional peak was determined. Also clarify the following in Table legend as this is not currently understandable "...in a range of inhibition zone diameters and output by Normalised Resistance Interpretation (COWT)". We have provided reference to the universal protocol by Kronvall where all the details related to creation of functional peaks are explained including the online spreadsheet that is used in generating the breakpoint. We have also included explanation in the introduction about the functional peak.

Fig. 2: enlarge font of the y-axis (values and axis title). Also enlarge values on x-axis (x-axis title font is fine). – Done

Fig. 3: is it possible to use different colors to indicate the CB, ECOFFs and COWT dashed lines, to avoid confusion with the colors used for the different antimicrobials? – this was already done in the figure as all breakpoints were in different colours

Table 2: why are ECOFFS values used for distinguishing %WT and %R? or should WT be S here? - I don't understand this question but we have followed the naming conventions

Lines 251-256: In line 254, is ECOFFS prevalence significantly different from both CB and COWT prevalence or only from one of the 2? Should a correction for multiple testing be applied here (because 2 comparisons were done)? What is the difference between the tests described in lines 251-254 and in line 255-256? In the first part of the comparison, we compare difference in prevalence estimates across all antimicrobial classes according to COWT and CB In the second part we compare prevalence estimates of all the three breakpoints across all antibiotics expect tetracycline.

Line 272: should ECOFF be CB here? As CB and COWT were not significantly different. – This has now been clarified. (In 299-306)

Line 273: add "from both COWT and CB" (if this is true; see my comment about lines 251-254 above) - This has been clarified (In 299-306)

---

## VERSION 1

---

### Editor recommendation and comments

<https://doi.org/10.1099/acmi.0.000540.v1.5>

© 2023 de Dios R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License.

**Rubén de Dios**; Brunel University London, Life Sciences, UNITED KINGDOM

Date report received: 28 March 2023

Recommendation: Major Revision

**Comments:** In this manuscript, Maganga et al. present an AMR epidemiology study of *E. coli* isolates in poultry farms and compare it with various clinical and microbiological AMR breakpoints. The premise of this study seems interesting, as the authors point out indications of a bias in the current standard breakpoints for different antibiotics. However, several concerns have emerged after the review process. Please, address the reviewers' suggestions and comments thoroughly, especially those concerning: • Lack of clarity in the Results section and availability of the source material information. • Transparency of the methodology. • Preliminary explanations of some key concepts (for example, COWt, functional peak...) to make the text more readable for non-experts • Coherence of the points mentioned in the Discussion section and their relation with the results. Please, provide a revised manuscript containing all suggestions and a point-by-point response to the reviewers' comments within 1 month.

---

### Reviewer 2 recommendation and comments

<https://doi.org/10.1099/acmi.0.000540.v1.4>

© 2023 Anonymous. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License.

**Anonymous.**

Date report received: 28 March 2023

Recommendation: Minor Amendment

**Comments:** This manuscript compares 3 different phenotypic antimicrobial testing methods to calculate clinical or microbiological breakpoints of bacterial isolates, using a set of approximately 70 *E. coli* poultry isolates from various different farms and farm types in Tanzania. The main findings are that ECOFFS breakpoints tend to be higher than clinical breakpoints or the relatively new method of NRI. Also, the authors observe unexpected prevalence of imipenem and ceftazidime resistance in poultry isolates, which they speculate may be related to resistance genes present in the local water reservoirs. Overall, the manuscript is straightforward, well written and easy to understand. However, in some cases the Results section lacks clarity and the Methodology lacks detail - to address these issues I have a list of minor corrections below that the authors should address before publication. Line 86: remove 'the' before Europe Line 117: what is meant by 'wards' here? I only know this term in a hospital context so please



clarify. Also not clear if there are 10 wards total, or 10 for each district (presume the latter as this adds up to 800 total but please clarify). Lines 127 and 330: change gram to Gram Line 130: clarify what is meant by 'plain' plates Line 140/141: what is meant by 'one vial is archived' as opposed to 'the other preserved at -80 in glycerol'? What does the archiving entail? The results section lacks clarity. What isolates are used in the susceptibility testing in Table 1 and Fig. 2? Does this refer to the E. coli positive control? If so please indicate. Line 215/216: "In at least one antimicrobial, there was one isolate with a 6mm zone diameter". What do the authors mean? According to Fig. 2 there is at least one isolate with 6mm zone for each of the 4 tested antimicrobials. Line 216/217: "Except for tetracycline, the wild type cut-off (COWT) was lower than CB and ECOFFS". Where can I see this? Or if not visualized, please put between brackets the actual CB and ECOFFS values. Table 1: please indicate how the functional peak was determined. Also clarify the following in Table legend as this is not currently understandable "...in a range of inhibition zone diameters and output by Normalised Resistance Interpretation (COWT)". Fig. 2: enlarge font of the y-axis (values and axis title). Also enlarge values on x-axis (x-axis title font is fine). Fig. 3: is it possible to use different colors to indicate the CB, ECOFFS and COWT dashed lines, to avoid confusion with the colors used for the different antimicrobials? Table 2: why are ECOFFS values used for distinguishing %WT and %R? or should WT be S here? Lines 251-256: In line 254, is ECOFFS prevalence significantly different from both CB and COWT prevalence or only from one of the 2? Should a correction for multiple testing be applied here (because 2 comparisons were done)? What is the difference between the tests described in lines 251-254 and in line 255-256? Line 272: should ECOFF be CB here? As CB and COWT were not significantly different.. Line 273: add "from both COWT and CB" (if this is true; see my comment about lines 251-254 above)

*Please rate the manuscript for methodological rigour*

Good

*Please rate the quality of the presentation and structure of the manuscript*

Good

*To what extent are the conclusions supported by the data?*

Strongly support

*Do you have any concerns of possible image manipulation, plagiarism or any other unethical practices?*

No

*Is there a potential financial or other conflict of interest between yourself and the author(s)?*

No

*If this manuscript involves human and/or animal work, have the subjects been treated in an ethical manner and the authors complied with the appropriate guidelines?*

Yes

---

## Reviewer 1 recommendation and comments

<https://doi.org/10.1099/acmi.0.000540.v1.3>

© 2023 Anonymous. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License.

### Anonymous.

Date report received: 15 March 2023

Recommendation: Major Revision

**Comments:** In this work, the authors identify a number of E. coli isolates from poultry farms and assess their antimicrobial resistance profile for four antibiotics, showing discrepancies on if they should be considered resistant or sensitive depending on the breakpoints (ECOFFS, CLSI, NRI). The premise is valid, since it is true that different standard uses will give different results. However, it is also true that the main standards (ECOFFS and CLSI) are used for different purposes (lines 82-85). Furthermore, I have my concerns on the applicability of using an NRI method as standard, as according to it, an isolate will be resistant or not depending on the sample, a criterion that cannot be applied in the clinic (which is the original point of these standards). Nevertheless, it is obvious that the ECOFFS and CSLI breakpoints differ by far, so this is debate worth having. From the literature point of view, the reference format seems a bit messy, and should be eventually adjusted to the guidelines of this platform. I would also suggest that the authors improve the fluency of the manuscript and the readability. For example, in the results section, each paragraph should start with the objective of the experiment or an introduction linking to the previous section, and finish with the conclusion of the experiment and its meaning. This is missing in all the section and makes it difficult to read and to keep track of the information shown. I hope my recommendations help improving the quality of this manuscript. Some other minor

amendments could be made, but the changes proposed are extensive enough to leave the small details for a future corrected version. Please see the following specific comments. Specific comments L78: in microbiology, usually a wild type is a strain as it is found in nature, no matter what phenotype or genotype it has. Here, this concept is different, but would only be explained several lines below. I would tackle this distinction at this point, or else it might confuse some readers. L82-85: this sentence seems to imply that the EUCAST standards do not have clinical applicability at all. More clarity is needed here. L86: change "the Europe" by "Europe". L89: At this point, please give a clear explanation of how the NRI method works and its applicability. As it is explained, it seems very limited and the results might not be comparable to other samples/laboratories/regions. L90: here the authors mention a distinction between WT and NWT. However, this definition is still different from the general use of this expression in microbiology. Please clarify. L105: change "current" to "present". L118: where in Glasgow and which analyses were performed there? L123: I assume "Caudell" refers to reference 15, however this is not in the reference list. L125: if coliforms were assessed as resistant according to CLSI standards, would this not be biased according to this work? I suggest that the authors give a justification for this or at least a reflection. L133: Please clarify where each experiment was performed. L137: Please explain the standardised protocol for the sake of reproducibility. L145-149: was this performed in the same experimental batch as in the previous section? Either way, if the methodology is the same, the authors can refer to that section rather than repeating. L153: Please explain the standardised protocol for the sake of reproducibility. L167-173: why use this method rather than 16S rRNA sequencing? L191: tigecycline belongs to the same antibiotic family as tetracycline, but it is not analogous to it. Please justify why the authors consider appropriate substituting one for the other. L207: Are the different isolates individually labelled/barcoded? As they are mentioned, the reader cannot know which of them correspond to each result. This information must be made available. L211: Figure 1 is not cited in the text. Furthermore, it merely shows a calibration curve. It would much more appropriate to show the actual qPCR results compared to a negative and positive control. L215-216: This is a clear example of the need to improve clarity. The sentence "In at least one antimicrobial, there was one isolate with a 6 mm zone diameter". These sentence does not offer any information and, as there is no individualised information of the isolates, the reader cannot be able to track it. Also, to the best of my knowledge, 6-7 mm is the usual size of the antibiotic discs used for disc diffusion assays. Does this mean this grew to the edge of the disc? L220: does this issue with the SD mean the results are not reliable? L225: what is the functional peak? L237: how would this compare to the CLSI breakpoints? L251: what is the prevalence estimate for cipro? L253: previously, the authors had mentioned that they would consider breakpoints for tigecycline as they are not available for tetracycline. However, here the authors consider all breakpoints except the one for tetracycline as it is not available. Please clarify this. L272: here ECOFFS should be CLSI breakpoint? L285-286: here the authors reach the idea that NRI interpretation might be affected by the dataset. Can the authors elaborate on how the application of this method can contribute to standardisation? L294-295: speaking of prevalence, the authors consider it high, low or moderate with respect to what? L323: I have my doubts that imipenem can be used informally. As a last resort antibiotic, not only it is restricted, but also rather expensive in comparison to other antibiotics. Anyway, can the authors give a reason why they think this antibiotic is informally used? Would there be any alternative explanation? L327-330: this sentence confuses me. According to my interpretation of Figure 3, all CB and COWT values are below the ECOFFS threshold, making them more restrictive in the definition of a resistant isolate. Can the authors clarify how those isolates could be misclassified as resistant according to ECOFFS in comparison to the other standards? L332-333: The authors should elaborate more on how the differences between the human and ruminant digestive tract relate to this study. L334: hyperefflux and antibiotic resistance are widely known to be linked. There are many more recent works in the literature the authors can refer to give a more comprehensive view of this. L334-338: the authors mention differences in the resistance prevalence in birds from pristine environments with respect to the results of this work, obtained from farm chickens, and justify it by methodological discrepancies. To me, it is very obvious that those two sample groups were not expected to give similar results, and that differences might be affected by the methodology, but I do not think that is the main cause of the discrepancies between these two particular studies.

*Please rate the manuscript for methodological rigour*

Poor

*Please rate the quality of the presentation and structure of the manuscript*

Very poor

*To what extent are the conclusions supported by the data?*

Partially support

*Do you have any concerns of possible image manipulation, plagiarism or any other unethical practices?*

No

*Is there a potential financial or other conflict of interest between yourself and the author(s)?*

No

*If this manuscript involves human and/or animal work, have the subjects been treated in an ethical manner and the authors complied with the appropriate guidelines?*

Yes

---

### **SciScore report**

<https://doi.org/10.1099/acmi.0.000540.v1.1>

© 2022 The Authors. This is an open-access article report distributed under the terms of the Creative Commons License.

### **iThenticate report**

<https://doi.org/10.1099/acmi.0.000540.v1.2>

© 2022 The Authors. This is an open-access article report distributed under the terms of the Creative Commons License.